Ninety-four U.S. students who acquired diarrhea in Mexico were treated with furazolidone (47 subjects) or ampicillin (47 subjects) on a double-blind random basis. Of 47 students, 26 (55%) who received furazolidone (100 mg four times daily for 5 days) recovered from illness wit-hin 48 h after initiation of therapy, in contrast to 15 of 47 (32%) who received ampicillin (500 mg four times daily for 5 days) (P < 0.05). Altogether, 74% of students treated with furazolidone and 49% of those receiving ampicillin were well within 72 h (P < 0.05). When furazolidone was compared with ampicillin, clinical illness was shortened on the average from 65 to 61 h for enterotoxigenic Escherichia coli diarrhea, from 83 to 58 h for shigellosis, fromn 82 to 51 h for diarrhea unassociated with a detectable agent, and from 72 to 57 h for all cases irrespective of etiology. Although not dramatically effective in the current trial, the broad spectrum of activity of furazolidone is of interest. Because of in vitro activity against Campylobacter strains and known effectiveness in treating giardiasis, furazolidone should be considered in therapy for diarrhea of unknown etiology in certain settings when laboratory processing of stools for etiological agent is not feasible.
Previous studies have shown that a majority of the cases of diarrhea which occur when persons travel from industrialized countries to developing regions are caused by bacterial pathogens (7, 17) . The most important agents in this setting ate enterotoxigenic Escherichia coli, Shigella, Salmonella, and Campylobacter strains. Trimethoprim-sulfamethoxazole (TMP-SMX) is an effective form of therapy for traveler's diarrhea (7) . It is not active against Campylobacter strains, which is a limiting factor in the empiric therapy of acute diarrhea in general. Recently, we carried out an in vitro study wherein 243 bacterial enteropathogens obtained from various parts of the world were tested for their susceptibility to antimicrobial agents (2) . We were impressed with the high degree of activity of furazolidone against all strains of enteropathogens tested, with the exception of a few strains of Yersinia enterocolitica. Since furazolidone was found to be active against the important agents of traveler's diarrhea, the present study was designed. Ampicillin was selected as a control, recognizing that it is not considered to be the current treatment of choice for traveler's diarrhea. However, ampicillin is widely used in Mexico for diarrhea, and a majority of the bacterial enteropathogens we have obtained ih the last 2 years from Mexico have been shown to be susceptible to the drug. Furthermore, information was already available as to the clinical response of the illness in the population under study when other active compounds (TMP-SMX and bicozamycin) were employed in previous studies (7, 8) .
MATERIALS AND METHODS
The study population comprised 100 male and female students from the United States enrolled in summer programs sponsored by the Universities of San Diego and Arizona in Guadalajara, Mexico. The criterion for admission * Corresponding author.
to the study was diarrhea of -60-h duration. Diarrhea was defined as the passage of four or more unformed stools in 24 h or three unformed stools in an 8-h period. Each subject also had to have at least one sign or symptom of gastrointestinal infection: nausea, vomiting, abdominal pain or cramps, or fever. After informed consent was obtained, a freshly passed unformed stool was collected and submitted to the field-site laboratory for enteropathogen detection by previously published methods (17a). Stools were examined for Shigella, Salmonella, Campylobacter, and Aeromonas isolates and protozoal parasites in our Guadalajara laboratory. Five E. coli colonies from each diarrheal stool were studied for enterotoxigenicity (both heat-stable [ST] and heat-labile [LT] enterotoxins) in Houston (6) .
For bacterial enteropathogen strains that remained viable, antimicrobial susceptibility testing was later performed in Houston by Kirby-Bauer disk diffusion methods.
Identical encapsulation of the furazolidone and ampicillin allowed a double-blind study to be performed, with the students randomly assigned to receive one of the two trial medications. The dosing regimens were one 100-mg capsule four times daily (furazolidone) or one 500-mg capsule four times daily (ampicillin). Both antibiotics were prescribed for 5 days. During the 5-day treatment period, patients were required to keep a daily diary of the number and consistency of stools, associated signs and symptoms of enteric illness, and the medication dosing schedule. In addition, they were required to report daily to the clinic for evaluation.
As found in previous clinical trials in this population, the best parameter of drug efficacy is time from initiation of therapy until the passage of the last unformed stool (7, 8) . In this trial, the students were considered to have recovered when the last unformed stool was passed and other signs and symptoms of enteric infection were no longer present.
Statistical analysis of data was done with the Wilcoxon rank-sum test, with Z corrected for ties, chi-square, or Fisher's exact test, as appropriate. Significance was defined as a P value less than or equal to 0.05.
RESULTS
Five students failed to complete the study or were dropped from the trial for a variety of reasons, including having a parasite in diarrheal stools, early return to the United States, or taking of a second antibiotic concomitantly. A sixth student who received furazolidone developed a rash during therapy and was removed from the study because of the adverse reaction. The rash was limited to both wrists, a knee, the sole of a foot, and both hands. The study population comprised 94 subjects. Patients in both treatment groups reported a similar duration of illness and severity of symptoms before enrollment in the trial. similar to those for the unstratified groups were seen and favored those treated with furazolidone. Table 2 shows the response to treatment in mean number of hours from initiation of therapy until passage of the last unformed stool. The differences were not significant by Wilcoxon rank-sum test. However, in all strata except Salmonella sp., the mean duration of diarrhea was shorter in the furazolidone group.
Two subjects given furazolidone, one with enterotoxigenic E. coli infection and one with an unknown agent, and two persons treated with ampicillin (both unknown causes) worsened on therapy and were declared treatment failures. They were removed from the study and given TMP-SMX. In addition, 8 furazolidone-treated students (2 with enterotoxigenic E. coli, 2 with Shigella sonnei, 1 with enterotoxigenic E. coli plus S. sonnei, 1 with Salmonella B, 1 with enterotoxigenic E. coli plus Aeromonas sp., and 1 with an unknown agent) and 10 ampicillin-treated individuals (4 with enterotoxigenic E. coli, 2 with S. sonnei, 2 with entertoxigenic E. coli plus S. sonnei, and 2 with unknown agents) still had not passed a formed stool within the 5 days of therapy. We considered these subjects to also be treatment failures, making the frequency of treatment failures 21% for furazolidone and 26% for ampicillin.
We examined the susceptibility of a majority of enterotoxigenic E. coli, Shigella, and Salmonella strains isolated from students treated with either drug. In the furazolidone-treated group, all strains tested were susceptible to furazolidone, including 13 enterotoxigenic E. coli, 11 However, furazolidone has some advantages in therapy for acute diarrhea that are not apparent in this trial. Furazolidone has previously been shown to be active against a variety of agents not commonly encountered by the U.S. student population in Mexico. In cholera, furazolidone has been shown to be as effective as tetracycline in reducing the duration of diarrhea, Vibrio excretion, and intravenous fluid requirements among adults and children (3, 13) . Also, this drug is currently the recommended agent in therapy for giardiasis in infants and young children, since there exists a pediatric suspension form and cure rates are higher due to better acceptability (4) . Although the published data offer various results as to the relative effectiveness of furazolidone, quinacrine, and metronidazole in therapy for giardiasis, all three are effective in more than 80% of cases (1, 4, 14, 18, 19) . Furazolidone may be active against certain forms of bacteremic salmonellosis (10, 12) 
